Cas:169209-65-8 2-amino-2-(4-phosphonophenyl)propanoic acid manufacturer & supplier

Chemical Name:2-amino-2-(4-phosphonophenyl)propanoic acid

CAS.NO:169209-65-8

Synonyms:mppg;MFCD00672651

Molecular Formula:C₉H₁₂NO₅P

Molecular Weight:245.16900

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:130.66000

Exact Mass:245.04500

LogP:0.44840

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like mppg chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00672651 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,mppg Use and application,mppg technical grade,usp/ep/jp grade.

Related News: The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy. 2-amino-2-(4-phosphonophenyl)propanoic acid manufacturer The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy. 2-amino-2-(4-phosphonophenyl)propanoic acid supplier “The synergies among our Regulatory, Clinical and Real-World Evidence (RWE) practices and CROS NT’s global biometrics capabilities will enhance Alira Health’s unique ability to serve clients across their solutions lifecycle,” said CEO Gabriele Brambilla in a statement. 2-amino-2-(4-phosphonophenyl)propanoic acid vendor The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy. 2-amino-2-(4-phosphonophenyl)propanoic acid factory Many branded versions of drugs are currently more expensive in China than in other major markets. They could now be subjected to a centralized procurement program where manufacturers will have to go through a bidding process to get the right to supply drugs to public hospitals, the National Health Commission said in a document published on late Friday.